Core Viewpoint - PharmaCorp RX Inc. has filed a preliminary short form base shelf prospectus to qualify the distribution of up to $100 million in various securities over a 25-month period, enhancing its ability to access capital markets for growth and acquisitions [2][3]. Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [5]. - The company operates four pharmacies under the PharmaChoice Canada banner and aims to acquire more pharmacies, rebranding them under its platform [5]. Financial Strategy - The base shelf prospectus will allow PharmaCorp to issue common shares, preferred shares, warrants, debt securities, subscription receipts, units, or any combination thereof, based on financial requirements and market conditions [2]. - The specific terms of any offerings will be detailed in prospectus supplements filed with Canadian securities regulatory authorities [2]. Corporate Development - The filing of the base shelf prospectus is seen as a milestone in PharmaCorp's corporate development, providing flexibility to access capital markets as acquisition opportunities arise [3]. - The strategic alliance with PharmaChoice Canada is highlighted as a key factor in advancing the company's national growth and operations platform [3].

Core Viewpoint - The Dow Chemical Company ("TDCC") has announced a tender offer to purchase certain debt securities for an aggregate consideration of up to $1.0 billion, which includes securities from its subsidiaries Rohm and Haas and Union Carbide Corporation [1][10]. Group 1: Tender Offer Details - The tender offer is part of TDCC's strategy to manage its debt and is detailed in the Offer to Purchase dated February 25, 2025 [1][10]. - The early participation date for the tender offer was set for March 10, 2025, and the expected early settlement date is March 13, 2025 [5][6]. - Holders of validly tendered securities will receive total consideration in cash, which includes an early participation amount of $30 per series of securities [4][6]. Group 2: Securities Information - The tender offer includes various series of securities, with specific amounts and terms outlined, such as the 0.500% Notes Due 2027 and the 7.850% Debentures Due 2029, which have been accepted for purchase [3][9]. - The total consideration for each $1,000 or €1,000 principal amount of securities validly tendered includes accrued interest from the last payment date to the early settlement date [7][8]. - Due to the tender cap, not all tendered securities will be accepted; only specific amounts of certain securities will be purchased on a prorated basis [9]. Group 3: Financial Management - TDCC has retained Citigroup Global Markets Inc. and HSBC Securities (USA) Inc. as joint lead dealer managers for the tender offer, indicating a structured approach to managing the transaction [11]. - The company aims to optimize its capital structure through this tender offer, reflecting a proactive stance in financial management [1][10]. Group 4: Company Background - Dow Inc. operates as a leading materials science company with a focus on high-growth markets, achieving approximately $43 billion in sales in 2024 [14]. - Rohm and Haas and Union Carbide Corporation are wholly owned subsidiaries of TDCC, contributing to its diversified portfolio in chemicals and polymers [15].